Breast cancer is a heterogeneous group of malignancies with a spectrum of molecular subtypes, pathologies and outcomes that together comprise the most common non-cutaneous cancer in women. Currently, over 80% of breast cancer patients are diagnosed at relatively early stages of disease where there are encouraging data on outcomes and long term survival. However, there is currently no curative option for those patients with metastatic disease and there is a substantial medical need to identify effective and safe treatment options for these patients. One approach to improve cancer therapy is by designing therapeutics directed against targets with differential levels of expression on malignant versus normal cells with the goal of improving tumor selectivity and reducing damage to normal tissues. Antibody drug conjugates (ADCs) are a rapidly evolving therapeutic class that exploits the target-selectivity of monoclonal antibodies (MAbs) to deliver cytotoxic drugs to antigen-expressing cells (Lambert & Morris, 2017; Senter, 2009; Thomas, Teicher, & Hassan, 2016; Trail, 2013). The regulatory approval of ADCs for both hematologic malignancies (brentuximab vedotin) (Younes et al., 2010) and solid tumors (ado-trastuzumab emtansine) (Amiri-Kordestani et al., 2014; Verma et al., 2012) clearly demonstrates the clinical potential of ADCs. This review will focus on targets under consideration for breast cancer directed ADCs and on the technology modifications being considered to improve ADC efficacy and safety.

乳腺癌是恶性肿瘤的异质性组，具有一系列分子亚型，病理学和预后，共同构成女性中最常见的非皮肤癌。当前，超过80％的乳腺癌患者被诊断为处于疾病的相对早期阶段，那里有令人鼓舞的结果和长期生存数据。但是，目前对于那些患有转移性疾病的患者没有治愈的选择，并且迫切需要为这些患者确定有效和安全的治疗选择。改善癌症治疗的一种方法是设计针对针对恶性与正常细胞表达水平不同的靶标的治疗药物，目的是改善肿瘤的选择性并减少对正常组织的损伤。抗体药物偶联物（ADC）是一种快速发展的治疗类别，它利用单克隆抗体（MAb）的靶标选择性将细胞毒性药物递送至表达抗原的细胞（Lambert＆Morris，2017; Senter，2009; Thomas，Teicher，＆Hassan （2016年； Trail，2013年）。ADC对血液系统恶性肿瘤（brentuximab vedotin）（Younes等人，2010）和实体瘤（ado-trastuzumab emtansine）（Amiri-Kordestani等人，2014; Verma等人，2012）的监管批准清楚地表明了ADC的临床潜力。这篇综述将重点关注针对乳腺癌的ADC所考虑的目标，以及为提高ADC功效和安全性而考虑的技术改进。